Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DK1PA2
|
|||
| Drug Name |
225Ac-labelled aCD38
|
|||
| Drug Type |
Radiopharmaceutical therapy agent
|
|||
| Indication | Multiple myeloma [ICD-11: 2A83; ICD-10: C90] | Phase 1 | [1] | |
| Company |
Actinium Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cyclic ADP-ribose hydrolase 1 (CD38) | Target Info | . | [2] |
| KEGG Pathway | Nicotinate and nicotinamide metabolism | |||
| Metabolic pathways | ||||
| Calcium signaling pathway | ||||
| Hematopoietic cell lineage | ||||
| Oxytocin signaling pathway | ||||
| Salivary secretion | ||||
| Pancreatic secretion | ||||
| Epstein-Barr virus infection | ||||
| NetPath Pathway | Leptin Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| Panther Pathway | CCKR signaling map ST | |||
| WikiPathways | Oxytocin signaling | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02998047) A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma. U.S. National Institutes of Health. | |||
| REF 2 | Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.